← SEC 公告列表 | CADL SEC 公告 | Candel Therapeutics, Inc.（CADL）

重大事件 即時報告 8-K 2026-06-24

Candel Therapeutics年度股東大會結果出爐 選出四名董事並續聘KPMG

於 SEC 網站開啟原文

AI 繁中摘要

Candel Therapeutics（納斯達克：CADL）於2026年6月23日舉行年度股東大會，會後提交8-K報告披露投票結果。📋 股東選出四名Class II董事，任期至2029年年會：Edward J. Benz Jr.、Paul B. Manning、Maha Radhakrishnan及Paul Peter Tak。投票結果顯示，Benz博士獲得24,897,348票贊成、6,796,622票反對，另有22,175,525票為券商未投票（Broker Non-Votes）；其餘三位董事均以超過3,100萬票贊成、僅少量反對票通過。券商未投票佔比顯著，反映部分機構投資者未對董事選舉行使表決權。 此外，股東以壓倒性票數（53,543,020票贊成、238,508票反對、87,967票棄權）批准聘任KPMG LLP為公司截至2026年12月31日財政年度的獨立註冊會計師事務所。 本次會議無其他事項提交表決。✅ 董事會成員變動不大，管理層穩定性獲確認；會計師事務所的續聘亦保障財務報告的獨立性。對投資者而言，公司治理結構維持正常，短期內無重大治理風險。
展開英文正文 
8-K
 
 
 
 0001841387false00018413872026-06-232026-06-23

  

  
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 
 
 
 

 
 Date of Report (Date of earliest event reported): June 23, 2026

 

  
 
CANDEL THERAPEUTICS, INC.
(Exact name of Registrant as Specified in Its Charter)
 
 

 
 
 
 
 
 
 
 

 
 Delaware

 001-40629

 52-2214851

 

 
 (State or Other Jurisdiction
of Incorporation)

 (Commission File Number)

 (IRS Employer
Identification No.)

 

 
  

  

  

  

  

 

 
 117 Kendrick St
Suite 450

  

 

 
 Needham, Massachusetts

  

 02494

 

 
 (Address of Principal Executive Offices)

  

 (Zip Code)

 

  

 
 
 
 

 
 Registrant’s Telephone Number, Including Area Code: (617) 916-5445

 

  

 
 
 
 

 
 Not Applicable

 

 (Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:

 
 
 
 
 
 
 
 

 
 
Title of each class

  

 Trading
Symbol(s)

  

 
Name of each exchange on which registered

 

 
 Common Stock, $0.01 par value per share

  

 CADL

  

 The Nasdaq Global Market

 

 Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). 
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 

  
 

 
  

 Item 5.07 Submission of Matters to a Vote of Security Holders.
Candel Therapeutics, Inc., a Delaware corporation (the “Company”), held its Annual Meeting of Stockholders (the “Annual Meeting”) on June 23, 2026. As of April 24, 2026, the record date for the Annual Meeting, there were 73,270,239 outstanding shares of the Company’s voting common stock. The Company’s stockholders voted on the following matters, which are described in detail in the Company’s Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 29, 2026: (i) to elect four Class II directors, Edward J. Benz, Jr., M.D., Paul B. Manning, Maha Radhakrishnan, M.D., and Paul Peter Tak, M.D., Ph.D., FMedSci, to serve until the Company’s 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, subject to their earlier death, resignation or removal (“Proposal 1”) and (ii) to ratify the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 (“Proposal 2”).
The Company’s stockholders elected each of the Class II director nominees, Edward J. Benz, Jr., M.D., Paul B. Manning, Maha Radhakrishnan, M.D., and Paul Peter Tak, M.D., Ph.D., FMedSci, recommended for election at the Annual Meeting in Proposal 1. The votes cast at the Annual Meeting were as follows:
 

 
 
 
 
 
 
 
 
 
 

 
  

  

 For

  

 Withheld

  

 Broker Non-Votes

 

 
 Edward J. Benz, Jr., M.D.

  

 24,897,348

  

 6,796,622

  

 22,175,525

 

 
 Paul B. Manning

  

 31,591,618

  

 102,352

  

 22,175,525

 

 
 Maha Radhakrishnan, M.D.

  

 31,047,706

  

 646,264

  

 22,175,525

 

 
 Paul Peter Tak, M.D., Ph.D., FMedSci

  

 31,414,668

  

 279,302

  

 22,175,525

 

  
The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, recommended for ratification in Proposal 2 at the Annual Meeting. The votes cast at the Annual Meeting were as follows:
 

 
 
 
 
 
 
 
 

 
 For

  

 Against

  

 Abstain

 

 
 53,543,020

  

 238,508

  

 87,967

 

  
No other matters were submitted to or voted on by the Company’s stockholders at the Annual Meeting.
 
 

  
 

 
  

 SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
 
 
 
 
 
 

 
  

  

  

 Candel Therapeutics, Inc.

 

 
  

  

  

  

 

 
 Date:

 June 24, 2026

 By: 

 /s/ Paul Peter Tak

 

 
  

  

  

 Paul Peter Tak, M.D., Ph.D., FMedSci
President and Chief Executive Officer